Gadolinium contrast agents for CNS imaging: Current concepts and clinical evidence

American Journal of Neuroradiology

Volumn 35, Issue 12, 2014, Pages 2215-2226

  Kanal, E ^a   Maravilla, K ^b   Rowley, H A ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE;

ALLERGIC REACTION; ANXIETY; BASILAR ARTERY; BEHAVIOR DISORDER; BRAIN PERFUSION; CENTRAL NERVOUS SYSTEM IMAGING; CONTRAST ENHANCEMENT; FEAR; HUMAN; INTERNAL CAROTID ARTERY; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE CEREBRAL ARTERY; NAUSEA AND VOMITING; NEPHROGENIC SYSTEMIC FIBROSIS; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; SAFETY; SCINTIGRAPHY; STEADY STATE; STEADY STATE IMAGING; COMPUTER ASSISTED DIAGNOSIS; PROCEDURES;

CONTRAST MEDIA; GADOLINIUM; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; NEUROIMAGING;

EID: 84919473489     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A3917     Document Type: Review

References (86)

1. Dotarem product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204781s000lbl.pdf. Accessed May 10, 2013.
2. Gadavist product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201277s000lbl.pdf. Accessed May 10, 2013.
3. Magnevist product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/019596s051lbl.pdf. Accessed May 10, 2013.
4. MultiHance product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021357s009lbl.pdf. Accessed May 10, 2013.
5. Omniscan product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020123s037lbl.pdf. Accessed May 10, 2013.
6. Opti MARK product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020937s016lbl.pdf. Accessed 10 May 10, 2013.
7. ProHance product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020131s024lbl.pdf. Accessed May 10, 2013.
8. Ablavar product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021711s003lbl.pdf. Accessed May 10, 2013.
9. Eovist product label. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022090s004lbl.pdf Accessed May 10, 2013.
10. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: An overview. Eur J Radiol 2008;66:160-67.
11. Rohrer M, Bauer H, Mintorovitch J, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005;40:715-24.
12. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: A new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997;32:780-96.
13. Giesel FL, von Tengg-Kobligk H, Wilkinson ID, et al. Influence of human serum albumin on longitudinal and transverse relaxation rates (R1 and R2) of magnetic resonance contrast agents. Invest Radiol 2006;41:222-28.
14. Pintaske J, Martirosian P, Graf H, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadavist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5, and 3 Tesla. Invest Radiol 2006;41:213-21, Erratum in Invest Radiol 2006;41:859.
15. Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 2006;1:128-37.
16. Yuh WT, Fisher DJ, Engelken JD, et al. MR evaluation of CNS tumors: dose comparison study with gadopentetate dimeglumine and gadoteridol. Radiology 1991;180:485-91.
17. Myhr G, Rinck PA, Børseth A. Gadodiamide injection and gadopentetate dimeglumine: A double-blind study in MR imaging of the CNS. Acta Radiol 1992;33:405-09.
18. Balériaux D, Matos C, De Greef D. Gadodiamide injection as a contrast medium for MRI of the central nervous system: A comparison with gadolinium-DOTA. Neuroradiology 1993;35:490-94.
19. Valk J, Algra PR, Hazenberg CJ, et al. A double-blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MRI of the central nervous system. Neuroradiology 1993;35:173-77.
20. Brugières P, Gaston A, Degryse HR, et al. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd- DTPA and Gd-DOTA). Neuroradiology 1994;36:27-30.
21. Akeson P, Jonsson E, Haugen I, et al. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA. Neuroradiology 1995;37:229-33.
22. Oudkerk M, Sijens PE, van Beek EJ, et al. Safety and efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system. Invest Radiol 1995;30:75-78.
23. Grossman RI, Rubin DI, Hunter G, et al. Magnetic resonance imaging in patients with central nervous system pathology: q comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA). Invest Radiol 2000;35:412-19.
24. Runge VM, Armstrong MR, Barr RG, et al. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology. Invest Radiol 2001;36:65-71.
25. Runge VM, Parker JR, Donovan M. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain. Invest Radiol 2002;37:269-80.
26. Greco A, Parker JR, Ratcliffe CG, et al. Phase III, randomized, double blind, crossover comparison of gadoteridol and gadopentetate dimeglumine in magnetic resonance imaging of patients with intracranial lesions. Australas Radiol 2001;45:457-63.
27. Anzalone N, Gerevini S, Scotti R, et al. Detection of cerebral metastases on magnetic resonance imaging: intraindividual comparison of gadobutrol with gadopentetate dimeglumine. Acta Radiol 2009;50:933-40.
28. Kim ES, Chang JH, Choi HS, et al. Diagnostic yield of double-dose gadobutrol in the detection of brain metastasis: intraindividual comparison with double-dose gadopentetate dimeglumine. AJNR Am J Neuroradiol 2010;31:1055-58.
29. Katakami N, Inaba Y, Sugata S, et al. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0M compared with gadoteridol: A multicenter, phase II/III study in patients with known or suspected brain metastases. Invest Radiol 2011;46:411-18.
30. Koenig M, Schulte-Altedorneburg G, Piontek M, et al. Intra-individual, randomised comparison of theMRIcontrast agents gadobutrol versus gadoteridol in patients with primary and secondary brain tumours, evaluated in a blinded read. Eur Radiol 2013;23:3287-95.
31. Center for Drug Evaluation and Research. FDA Advisory Committee Briefing Document. New Drug Application 201-277. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm255169.pdf. Accessed February 6, 2014.
32. Anzalone N, Scarabino T, Venturi C, et al. Cerebral neoplastic enhancing lesions: Multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting. Eur J Radiol 2013;82:139-45.
33. Colosimo C, Ruscalleda J, Korves M, et al. Detection of intracranial metastases: A multicenter, intrapatient comparison of gadobenate dimeglumine-enhanced MRI with routinely used contrast agents at equal dosage. Invest Radiol 2001;36:72-81.
34. Knopp MV, Runge VM, Essig M, et al. Primary and secondary brain tumors at MR imaging: bicentric intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2004;230:55-64.
35. Colosimo C, Knopp MV, Barreau X, et al. A comparison of Gd- BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours. Neuroradiology 2004;46:655-65.
36. Essig M, Tartaro A, Tartaglione T, et al. Enhancing lesions of the brain: intra-individual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators. Academic Radiology 2006;13:744-51.
37. Maravilla KR, Maldjian JA, Schmalfuss IM, et al. Contrast enhancement of central nervous system lesions: Multicenter intraindividual crossover comparative study of two MR contrast agents. Radiology 2006;240:389-400.
38. Kuhn MJ, Picozzi P, Maldjian JA, et al. Evaluation of intraaxial enhancing brain tumors on magnetic resonance imaging: intraindi gadopentetate dimeglumine for visualization and assessment, and implications for surgical intervention. J Neurosurg 2007;106:557-66.
39. Rowley HA, Scialfa G, Gao PY, et al. Contrast-enhancedMRimaging of brain lesions: A large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008;29:1684-91.
40. Rumboldt Z, Rowley HA, Steinberg F, et al. Multicenter, doubleblind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 Tesla. J Magn Reson Imaging 2009;29:760-67.
41. Seidl Z, Vymazal J, Mechl M, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012;33:1050-58.
42. Griffiths PD, Wilkinson ID, Wels T, et al. Brain MR perfusion imaging in humans. Acta Radiol 2001;42:555-59.
43. Griffiths PD, Pandya H, Wilkinson ID, et al. Sequential dynamic gadolinium magnetic resonance perfusion-weighted imaging: Effects on transit time and cerebral blood volume measurements. Acta Radiol 2006;47:1079-84.
44. Giesel FL, Mehndiratta A, Risse F, et al. Intraindividual comparison between gadopentetate dimeglumine and gadobutrol for magnetic resonance perfusion in normal brain and intracranial tumors at 3 Tesla. Acta Radiol 2009;50:521-30.
45. Essig M, Lodemann KP, Le-Huu M, et al. Intraindividual comparison of gadobenate dimeglumine and gadobutrol for cerebral magnetic resonance perfusion imaging at 1.5 T. Invest Radiol 2006;41:256-63.
46. Thilmann O, Larsson EM, Bjorkman-Burtscher IM, et al. Comparison of contrast agents with high molarity and with weak protein binding in cerebral perfusion imaging at 3 T. J Magn Reson Imaging 2005;22:597-604.
47. Wirestam R, Thilmann O, Knutsson L, et al. Comparison of quantitative dynamic susceptibility-contrastMRIperfusion estimates obtained using different contrast-agent administration schemes at 3T. Eur J Radiol 2010;75:e86-91.
48. Beranek-Chiu J, Froehlich JM, Wentz KU, et al. Improved vessel delineation in keyhole time-resolved contrast-enhanced MR angiography using a gadolinium doped flush. J Magn Reson Imaging 2009;29:1147-53.
49. Pediconi F, Fraioli F, Catalano C, et al. Gadobenate dimeglumine (Gd-BOPTA) vs gadopentetate dimeglumine (Gd-DTPA) for contrast- Enhanced magnetic resonance angiography (MRA): improvement in intravascular signal intensity and contrast to noise ratio. Radiol Med 2003;106:87-93.
50. Li Y, Li X, Li D, et al. Multicenter, intraindividual comparison of single-dose gadobenate dimeglumine and double-dose gadopentetate dimeglumine for MR angiography of the supra-aortic arteries (the Supra-Aortic Value Study). AJNR Am J Neuroradiol 2013;34:847-54.
51. Bultmann E, Erb G, Kirchin MA, et al. Intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for contrast-enhancedMRangiography of the supraaortic vessels at 3 Tesla. Invest Radiol 2008;43:695-702.
52. Kramer JH, Arnoldi E, François CJ, et al. Dynamic and static magnetic resonance angiography of the supra-aortic vessels at 3.0 T: intraindividual comparison of gadobutrol, gadobenate dimeglumine, and gadoterate meglumine at equimolar dose. Invest Radiol 2013;48:121-8.
53. Pirovano G, Munley J, Schultz C, et al. Nephrogenic systemic fibrosis: A review of published cases and results from three prospective observational studies. Insights Imaging 2012;3(suppl 1):S293.
54. Idée JM, Port M, Robic C, et al. Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 2009;30:1249-58.
55. Bennett CL, Qureshi ZP, Sartor AO, et al. Gadolinium-induced nephrogenic systemic fibrosis: The rise and fall of an iatrogenic disease. Clin Kidney J 2012;5:82-88.
56. Abujudeh HH, Kosaraju VK, Kaewlai R. Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: Experience with 21, 659 injections. AJR Am J Roentgentol 2010;194:430-34.
57. American College of Radiology. Manual on Contrast Media. Version 9. 2013. http://www.acr.org. Accessed January 4, 2013.
58. Bruder O, Schneider S, Nothnagel D, et al. Acute adverse reactions to gadolinium-based contrast agents in CMR: Multicenter experience with 17, 767 patients from the Euro CMR Registry. JACC Cardiovasc Imaging 2011;4:1171-76.
59. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR Am J Roentgenol 2001;176:1385-88.
60. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol: A highly concentrated macrocyclic gadolinium chelate: review of 14, 299 patients from observational trials. Eur J Radiol 2010;74:e186-92.
61. Murphy KP, Szopinski KT, Cohal RH, et al. Occurrence of adverse reactions to gadolinium-based contrast material and management of patients at increased risk: A survey of the American Society of Neuroradiology Fellowship Directors. Acad Radiol 1999;6:656-64.
62. Li A, Wong CS, Wong MK, et al. Acute adverse reactions to magnetic resonance contrast media: gadolinium chelates. Br J Radiol 2006;79:368-71.
63. Dillman JR, Ellis JH, Cohan RH, et al. Frequency and severity of acute allergic-like reactions to gadolinium-containing I.V. contrast media in children and adults. AJR Am J Roentgenol 2007;189:1533-38.
64. Hunt CH, Hartman RP, Hesley GK. Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456, 930 doses. AJR Am J Roentgenol 2009;193:1124-27.
65. Prince MR, Zhang H, Zou Z, et al. Incidence of immediate gadolinium contrast media reactions. AJR Am J Roentgenol 2011;196:W138-43.
66. Jung JW, Kang HR, Kim MH, et al. Immediate hypersensitivity reaction to gadolinium-based MR contrast media. Radiology 2012;264:414-22.
67. Vervloet D, Durham S. Adverse reactions to drugs. BMJ 1998;316:1511-14.
68. Hasdenteufel F, Luyasu S, Renaudin JM, et al. Anaphylactic shock after first exposure to gadoterate meglumine: Two case reports documented by positive allergy assessment. J Allergy Clin Immunol 2008;121:527-28.
69. Schiavino D, Murzilli F, Del Ninno M, et al. Demonstration of an IgE-mediated immunological pathogenesis of a severe reaction to gadopentetate dimeglumine. J Invest Allergol Clin Immunol 2003;13:140-42.
70. European Societyon Urogenital Radiology (ESUR).ESUR Guidelineson Contrast Media. Version 8.1. http://www.esur.org/esur-guidelines/. Accessed January 4, 2013.
71. United States of America ex rel. Lynch vs. Imagimed LLC, et al. (N.D. N.Y.); as reported on http://www.justice.gov/opa/pr/2013/August/13-civ-958.html. Accessed September 14, 2013.
72. Runge V. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging 2000;12:205-13.
73. Bleicher AG, Kanal E. Assessment of adverse reaction rates to a newly approved MRI contrast agent: review of 23, 553 administrations of gadobenate dimeglumine. AJR Am J Roentgenol 2008;191:W307-11.
74. Shellock FG, Parker JR, Venetianer C, et al. Safety of gadobenate dimeglumine (MultiHance): Summary of findings from clinical studies and postmarketing surveillance. Invest Radiol 2006;41:500-09.
75. Shellock FG, Parker JR, Pirovano G, et al. Safety characteristics of gadobenate dimeglumine: clinical experience from intra- And interindividual comparison studies with gadopentetate dimeglu-mine. J Magn Reson Imaging 2006;24:1378-85, Erratum in J Magn Reson Imaging 2007;26:217.
76. Weber JC. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drug. In: Rainsford KD, Velo GP, eds. Side Effects of Antiinflammatory/Analgesic Drugs Advances in Inflammation Research. Vol. 6. New York: Raven Press; 1984:1-7.
77. Lalli AF. Urographic contrast media reactions and anxiety. Radiology 1974;112:267-71.
78. Semelka RC, Hernandes Mde A, Stallings CG, et al. Objective evaluation of acute adverse events and image quality of gadoliniumbased contrast agents (gadobutrol and gadobenate dimeglumine) by blinded evaluation: pilot study. Magn Reson Imaging 2013;31:96 -101.
79. Davenport MS, Dillman JR, Cohan RH, et al. Effect of abrupt substitution of gadobenate dimeglumine for gadopentetate dimeglumine on rate of allergic-like reactions. Radiology 2013;266:773-82.
80. van Osch MJ, Vonken EJ, Wu O, et al. Model of the human vasculature for studying the influence of contrast injection speed on cerebral perfusion MRI. Magn Reson Med 2003;50:614-22.
81. Prokop M, Schneider G, Vanzulli A, et al. Contrast-enhanced MR angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine. Radiology 2005;234:399-408.
82. Gerretsen SC, le Maire TF, Miller S, et al. Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for MR angiography of peripheral arteries. Radiology 2010;255:988-1000.
83. Knopp MV, Giesel FL, von Tengg-Kobligk H, et al. Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging 2003;17:694-702.
84. Stein PD, Chenevert TL, Fowler SE, et al. Gadolinium-enhanced magnetic resonance angiography for pulmonary embolism: A multicenter prospective study (PIOPED III). Ann Intern Med 2010;152: 434-43, W142-43.
85. Woodard PK, Chenevert TL, Sostman HD, et al. Signal quality of single dose gadobenate dimeglumine pulmonary MRA examinations exceeds quality of MRA performed with double dose gadopentetate dimeglumine. Int J Cardiovasc Imaging 2012;28:295-301.
86. Wang J, Yan F, Liu J, et al. Multicenter, intra-individual comparison of single dose gadobenate dimeglumine and double dose gadopentetate dimeglumine for MR angiography of the peripheral arteries (the peripheral VALUE study). J Magn Reson Imaging 2013;38:926 -37.